Marshall Wace, LLP Avrobio, Inc. Transaction History

Marshall Wace, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.29 - $4.04 $60,257 - $188,712	-46,711 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$3.45 - $6.05 $122,305 - $214,478	35,451 Added 314.84%	46,711 $179,000
Q3 2021 Nov 15, 2021	BUY	$5.53 - $9.28 $62,267 - $104,492	11,260 New	11,260 $63,000
Q2 2021 Aug 13, 2021	SELL	$7.84 - $12.6 $429,577 - $690,391	-54,793 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$10.54 - $19.3 $577,518 - $1.06 Million	54,793 New	54,793 $695,000
Q1 2020 May 15, 2020	SELL	$10.08 - $27.21 $15,271 - $41,223	-1,515 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$13.05 - $21.88 $19,770 - $33,148	1,515 New	1,515 $30,000

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.